GlassScriptPhysician profile
Mahmut Y Celiker
NPI 1396782678
$1,095.57
in general payments reported to CMS, 2019-2025
15 companies · $230 in 2025
The $230 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2021: $89.13 · 2022: $157 · 2023: $305 · 2024: $192 · 2025: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $726.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $325.21 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $158.95 | 2019-2023 | |
| Pfizer INC. | $153.97 | 2023-2024 | |
| Agios Pharmaceuticals, INC. | $124.97 | 2025 | Pyrukynd |
| Takeda Pharmaceuticals U.S.A., INC. | $68.75 | 2021 | |
| Merck Sharp & Dohme LLC | $59.11 | 2022-2023 | Lynparza, Keytruda, Welireg |
| Puma Biotechnology, INC. | $36.63 | 2019-2025 | |
| Janssen Biotech, INC. | $34.52 | 2024-2025 | Carvykti, Darzalex, Tecvayli |
| Tesaro, INC. | $28.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $25.06 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $24.60 | 2023 | Tagrisso |
| Octapharma USA, INC. | $20.00 | 2023 | Panzyga |
| Tersera Therapeutics LLC | $18.53 | 2019 | |
| Sanofi-Aventis U.S. LLC | $17.27 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mahmut Celiker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.